189 related articles for article (PubMed ID: 15689327)
1. [Chronic myelogenous leukaemia: recent progress in biology and therapeutic strategies].
Turhan AG
Bull Cancer; 2005 Jan; 92(1):75-82. PubMed ID: 15689327
[TBL] [Abstract][Full Text] [Related]
2. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhäuser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T
J Clin Oncol; 2005 Oct; 23(30):7583-93. PubMed ID: 16234522
[TBL] [Abstract][Full Text] [Related]
3. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
4. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Walz C; Sattler M
Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
[TBL] [Abstract][Full Text] [Related]
5. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
[TBL] [Abstract][Full Text] [Related]
6. Recent advancements in the treatment of chronic myelogenous leukemia.
O'Dwyer ME; Mauro MJ; Druker BJ
Annu Rev Med; 2002; 53():369-81. PubMed ID: 11818480
[TBL] [Abstract][Full Text] [Related]
7. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
8. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
[TBL] [Abstract][Full Text] [Related]
9. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
[TBL] [Abstract][Full Text] [Related]
10. Roots of imatinib resistance: a question of self-renewal?
Burchert A
Drug Resist Updat; 2007; 10(4-5):152-61. PubMed ID: 17683977
[TBL] [Abstract][Full Text] [Related]
11. [Leukemogenesis and new therapy development: the example of chronic myelogenous leukemia].
Etienne G; Mahon FX
Bull Cancer; 2001 Jul; 88(7):651-8. PubMed ID: 11495816
[TBL] [Abstract][Full Text] [Related]
12. Resistance and relapse with imatinib in CML: causes and consequences.
Deininger M
J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S11-S21. PubMed ID: 18397677
[TBL] [Abstract][Full Text] [Related]
13. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
14. Glivec and CML: a lucky date.
Saglio G; Cilloni D; Rancati F; Boano L
J Biol Regul Homeost Agents; 2004; 18(2):246-51. PubMed ID: 15739279
[TBL] [Abstract][Full Text] [Related]
15. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
16. Chronic myeloid leukemia--advances in biology and new approaches to treatment.
Goldman JM; Melo JV
N Engl J Med; 2003 Oct; 349(15):1451-64. PubMed ID: 14534339
[No Abstract] [Full Text] [Related]
17. Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia.
Copland M; Fraser AR; Harrison SJ; Holyoake TL
Cancer Immunol Immunother; 2005 Apr; 54(4):297-306. PubMed ID: 15692843
[TBL] [Abstract][Full Text] [Related]
18. [Treatment strategies for chronic myeloid leukemia].
Jinnai I
Rinsho Ketsueki; 2005 Jan; 46(1):1-6. PubMed ID: 16708910
[No Abstract] [Full Text] [Related]
19. [Imatinib therapy for patients with chronic myelogenous leukemia].
Usui N
Gan To Kagaku Ryoho; 2005 Mar; 32(3):297-303. PubMed ID: 15791812
[TBL] [Abstract][Full Text] [Related]
20. First-Line management of CML: a state of the art review.
Hochhaus A
J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S1-S10. PubMed ID: 18397676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]